Close

Whistleblower Attorneys Blog

Updated:

GlaxoSmithKline Settles Good Manufacturing Process Violations for $750 for Contaminated and Defective Pills

The DOJ reported today that SB Pharmco Puerto Rico Inc., a subsidiary of GlaxoSmithKline, pleaded guilty to False Claims Act charges and agreed to a fine totaling $750 million. The total includes a criminal fine of $150 million and a civil False Claims Act fine of $600 million. This case…

Updated:

Senator Grassley Points to High Volume Prescribers as Likely Fraudsters

U.S. Senator Charles Grassley (R-Iowa), a long-time proponent of the False Claims Act and an anti-fraud advocate, has recently criticized reports of high-volume prescribers. In particular, Grassley addresses those prescribing extremely large quantities of mental health drugs. Recently, many pharmaceutical companies have agreed to large settlements involving the off-label promotion…

Updated:

Health Care Executives Targeted for Criminal Liability

In wake of many of the recent, massive pharmaceutical fraud settlements, government officials are exploring the possibility of holding pharmaceutical executives criminally liable for their company’s off-label promotion efforts. Despite the occurrence of massive settlements, many commentators and legal analysts believe they are simply the cost of doing business within…

Updated:

Fraud Case Asserting Substandard Pipe Strength Moves Forward Despite Delaware Withdrawal

Delaware recently withdrew its intervention in a False Claims Act case filed against J-M Manufacturing. Whistleblower John Hendrix, a former engineer for J-M Manufacturing in New Jersey, filed the suit against the manufacturer in 2006. Virginia, Tennessee, and Nevada remain in the suit, as well as 47 municipalities and water…

Updated:

False Claims Act Complaint Against Medtronic Dismissed

On November 17, 2008, two whistleblowers filed a qui tam action against Medtronic, a medical device manufacturer, alleging off-label promotion of Cardioplate, a heart device. The U.S. District Court in Houston recently granted Medtronic a motion to dismiss the case. The device is FDA approved for ablating (removing) tissue to…

Updated:

Green Mountain Coffee Faces SEC Fraud Suit

A securities fraud class-action lawsuit has been filed against Green Mountain Coffee Roasters Inc. in U.S. District Court in Vermont. The suit was originally brought by a whistleblower alleging accounting irregularities. Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC may award between 10 percent and 30…

Updated:

For-Profit Educational Fraud Addressed by Congress

On September 28, Senator Majority Whip Dick Durbin (D-IL) addressed Congress in an attempt to highlight the fraud-ridden for-profit education industry.  Durbin states that for-profit colleges receive the largest share of federal funding, yet are often under-performing. The University of Phoenix, DeVry University, and Kaplan University rank as the top…

Updated:

Merck Violates Foreign Corrupt Practices Act

New whistleblower provisions in the recently passed Dodd-Frank Act enable whistleblowers to receive rewards for reporting violations of the Foreign Corrupt Practices Act (FCPA). The FCPA prohibits bribery of foreign government officials in international business transactions and false entries in books and records of those companies within the statute. Whistleblowers…

Updated:

Pharmaceutical Sales Rep Plays Whistleblower for Second Time, Resulting in $520 Million Off-Label Promotion Settlement

AstraZeneca recently settled federal investigations regarding its marketing practices of Seroquel for $520 million.  Although Seroquel had only been approved by the FDA to treat schizophrenia and acute bipolar I disorder, whistleblower James Wetta accused the company of embarking on a national sales program to promote Seroquel for off-label use…

Contact Us